Abstract Background Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor, has demonstrated efficacy in advanced clear-cell renal cell carcinoma (ccRCC) in patients previously received immunotherapy (IO) and anti-angiogenics. However, comorbidities pose a challenge in cancer management and often limit inclusion...
Ali Hajj Ali, Liliana Ascione, R. Nawfal et al.· The Oncologist· 0 citations
Abstract Background Previous retrospective work found an association between earlier immune-checkpoint inhibitors (ICI) infusion times and survival outcomes in renal cell carcinoma (RCC). A recent randomized trial in non-small cell lung cancer (NSCLC) also reported benefit, however, a recent analysis of several randomi...
P. Barrios, Mustafa Saleh, Liliana Ascione et al.· The Oncologist· 0 citations
Hypoxia-inducible factor 2α (HIF-2α) is a central oncogenic driver in clear cell renal cell carcinoma (ccRCC) and a therapeutic target of the small-molecule inhibitor belzutifan. Genetic studies in murine models have suggested that hypoxia signaling may support T cell effector programs, raising concern that HIF-2α inhi...
Katrine N. Madsen, S. Kashima, H. Soulati et al.· Journal of Clinical Investig...· 0 citations
Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...
É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al.· The Oncologist· 0 citations
An in vitro RCC antigen model system was established to evaluate the impact of belzutifan on T-cell cytotoxicity and revealed that IL-2 and IFNG were among the most significantly downregulated genes in HIF2α knockout T cells.
S. Kashima, Katrine N. Madsen, H. Soulati et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.